Publications by authors named "Kumar Visvanathan"

Claim this Profile
E
Early Infliximab Levels and Clearance Predict Outcomes After Infliximab Rescue in Acute Severe Ulcerative Colitis: Results From PREDICT-UC.
Christopher F D Li Wai Suen, Matthew C Choy, Danny Con, Kaylene Cheng, Julie Nigro, Kumar Visvanathan

Gastroenterology· January 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effective real-world outcomes of remdesivir provided under compassionate access for moderate/severe COVID-19 in Australia.
Robert Stolz, Alice Liu, Jonathan Darby, Marion Kainer, Stephen Guy, Kumar Visvanathan

Intern Med J· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Follow-Up of Patients in a Prospective Study of NA Discontinuation Identifies Different Patterns of HBsAg Loss.
Simon J Hume, Samuel Hall, Gareth Burns, Sara Vogrin, Daniel Tassone, Kumar Visvanathan

Aliment Pharmacol Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High end-of-treatment hepatitis B core-related antigen levels predict hepatitis flare after stopping nucleot(s)ide analogue therapy.
Simon J Hume, Danny K Wong, Man-Fung Yuen, Kathy Jackson, Sara Bonanzinga, Kumar Visvanathan

Liver Int· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants.
Alexander J Thompson, Kathy Jackson, Sara Bonanzinga, Sam A L Hall, Simon Hume, Kumar Visvanathan

Hepatol Commun· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of a novel anterior nasal swab for the detection of SARS-CoV-2.
Amy Crowe, Yves Poy Lorenzo, Darren Jardine, Kumar Visvanathan

J Virol Methods· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of a novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study.
Jessica Howell, Huy Van, Minh D Pham, Rohit Sawhney, Fan Li, Kumar Visvanathan

Liver Int· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel point-of-care test for cirrhosis based on dimeric to monomeric IgA ratio in blood: a pilot cohort study.
Jessica Howell, Huy Van, Minh D Pham, Rohit Sawhney, Fan Li, Kumar Visvanathan

Hepatol Commun· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanocell COVID-19 vaccine triggers a novel immune response pathway producing high-affinity antibodies which neutralize all variants of concern.
Steven Y Gao, Nancy B Amaro-Mugridge, Jocelyn Madrid-Weiss, Nikolina Petkovic, Natasha Vanegas, Kumar Visvanathan

Front Immunol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diabetes IN hospital - Glucose and Outcomes in the COVID-19 pandemic (DINGO COVID-19): the 2020 Melbourne hospital experience prior to novel variants and vaccinations.
Rahul D Barmanray, Joanna Y Gong, Mervyn Kyi, Dev Kevat, Mohammad A Islam, Kumar Visvanathan

Intern Med J· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the cobas® HBV RNA investigational assay in the setting of nucleoside analog therapy cessation.
Kathy Jackson, Sara Bonanzinga, Ros Edwards, Kumar Visvanathan, Xin Li

J Med Virol· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis B Virus Flares After Nucleot(s)ide Analogue Cessation Are Associated With Activation of Toll-Like Receptor Signaling Pathways.
Samuel A L Hall, Gareth S Burns, Benjamin J Mooney, Rosemary Millen, Rachel Morris, Kumar Visvanathan

J Infect Dis· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of novel point-of-care test for alanine aminotransferase measurement: A pilot cohort study.
Jessica Howell, Huy Van, Minh Pham, Rohit Sawhney, Fan Li, Kumar Visvanathan

Clin Liver Dis (Hoboken)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis.
Samuel Anthony Lachlan Hall, Sara Vogrin, Olivia Wawryk, Gareth S Burns, Kumar Visvanathan

Gut· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels.
Samuel A L Hall, Gareth S Burns, Despina Anagnostou, Sara Vogrin, Vijaya Sundararajan, Kumar Visvanathan

Aliment Pharmacol Ther· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Very late-onset hepatitis B reactivation following chemoimmunotherapy.
Edward R Scheffer Cliff, Joe Sasadeusz, Kumar Visvanathan, Andrew Grigg

Leuk Lymphoma· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asian Pacific association for the study of liver (APASL) guidelines: hepatitis B virus in pregnancy.
Manoj Kumar, Zaigham Abbas, Milad Azami, Maria Belopolskaya, A K Dokmeci, Kumar Visvanathan

Hepatol Int· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B.
Edward J Gane, Hyung Joon Kim, Kumar Visvanathan, Yoon Jun Kim, Anh-Hoa Nguyen

Hepatology· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A qualitative exploration of enablers for hepatitis B clinical management among ethnic Chinese in Australia.
Yinzong Xiao, Jack Wallace, Alex Thompson, Margaret Hellard, Caroline van Gemert, Kumar Visvanathan

J Viral Hepat· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the TREAT-B score for hepatitis B treatment eligibility in a large Asian cohort: TREAT-B improves with age.
Jessica Howell, David Anderson, Stephen Bloom, John Lubel, William Kemp, Kumar Visvanathan

J Hepatol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Yin and the Yang of Treatment for Chronic Hepatitis B-When to Start, When to Stop Nucleos(t)ide Analogue Therapy.
Samuel Hall, Jessica Howell, Kumar Visvanathan, Alexander Thompson

Viruses· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD8 tumor-infiltrating lymphocytes within the primary tumor of patients with synchronous metastatic colorectal carcinoma do not track with survival.
Rosemary Millen, Shona Hendry, Vignesh Narasimhan, Rebecca Abbott, Matthew Croxford, Kumar Visvanathan

Clin Transl Immunology· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The QuantiFERON Monitor assay is predictive of infection post allogeneic hematopoietic cell transplantation.
Abby P Douglas, Lijia Yu, Vijaya Sundararajan, Jeff Szer, David Ritchie, Kumar Visvanathan

Transpl Infect Dis· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Serum alanine aminotransferase flares in chronic hepatitis B infection: the good and the bad.
Marc G Ghany, Jordan J Feld, Kyong-Mi Chang, Henry L Y Chan, Anna S F Lok, Kumar Visvanathan

Lancet Gastroenterol Hepatol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial.
Man-Fung Yuen, Kosh Agarwal, Edward J Gane, Christian Schwabe, Sang Hoon Ahn, Kumar Visvanathan

Lancet Gastroenterol Hepatol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis